查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1424907

轉化再生醫學市場：2024-2034

Translational Regenerative Medicine Market Report 2024-2034
出版日期: | 出版商: Visiongain | 英文 270 Pages | 商品交期: 最快1-2個工作天內

價格

預計到 2034 年，全球轉化再生醫學市場規模將以 24.3% 的複合年增長率成長。

由於慢性病的傳播，全球醫療保健格局正經歷典範轉移。 心血管疾病、糖尿病、神經退化性疾病和自體免疫疾病等疾病對全球衛生系統造成巨大負擔。 為了應對這一日益嚴重的健康危機，轉化再生醫學（TRM）領域的出現帶來了一線希望，它提供了解決慢性病根源的創新解決方案。

幹細胞療法、組織工程和其他再生方法有可能透過解決根本原因而不是簡單地控制症狀來改變慢性病的治療模式。 轉化再生醫學能夠開發適合個別患者需求的個人化治療。 這種方法特別適用於患者反應異質性普遍存在的慢性疾病。 幹細胞研究的進展，包括誘導多能幹細胞 (iPSC) 和成體幹細胞的使用，也提供了多種再生可能性。 基於幹細胞的治療在治療糖尿病等疾病方面顯示出了希望，它們可以透過替換受損的胰臟細胞來恢復正常的胰島素產生。

本報告調查了全球轉化再生醫學市場，提供了市場概況，分析了影響市場成長和市場機會的因素、市場規模的趨勢和預測，並對各個細分市場和地區進行了詳細分析。、競爭格局、主要概況公司等

目錄

第 1 章報告概述

第 2 章執行摘要

第3章市場概述

  • 主要發現
  • 市場動態
    • 市場驅動因素
    • 市場限制因素
    • 市場機會
  • 新冠肺炎 (COVID-19) 影響分析
  • 波特五力分析
  • PEST分析

第 4 章轉化再生醫學市場分析：依產品

  • 主要調查結果
  • 市場吸引力指數
  • 市場規模趨勢與預測
  • 幹細胞療法
    • 市場規模趨勢與預測
    • 市場規模趨勢與預測：按地區劃分
    • 市佔率：依地區劃分
    • 自體幹細胞療法
    • 同種異體幹細胞療法
  • 人體組織工程
    • 市場規模趨勢與預測
    • 市場規模趨勢與預測：按地區劃分
    • 市佔率：依地區劃分
    • 鷹架
    • 水凝膠
  • 基因治療
  • 其他
    • 市場規模趨勢與預測：按地區劃分
    • 市佔率：依地區劃分

第5章轉化再生醫學市場分析：依應用

  • 主要調查結果
  • 市場吸引力指數
  • 市場規模趨勢與預測
  • 腫瘤
  • 皮膚科
  • 肌肉骨骼系統
  • 神經病學
  • 心血管
  • 傷口癒合
  • 眼科
  • 其他
    • 市場規模趨勢與預測：按地區劃分
    • 市佔率：依地區劃分

第6章按地區劃分的轉化再生醫學市場分析

  • 主要調查結果
  • 市場規模趨勢與預測

第7章北美轉化再生醫學市場分析

第8章歐洲轉化再生醫學市場分析

第9章亞太轉化再生醫學市場分析

第10章拉丁美洲轉化再生醫學市場分析

第11章中東與非洲轉化再生醫學市場分析

第12章公司簡介

  • 競爭狀況
  • 戰略展望
  • Amgen Inc.
  • Anterogen Co., Ltd.
  • AVITA Medical, Inc.
  • Biosolutions Ltd.
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Integra LifeSciences
  • Mesoblast Ltd.
  • Novartis AG
  • Organogenesis Inc.
  • Sarepta Therapeutics, Inc.
  • Smith+Nephew
  • TERUMO BCT, INC.

第 13 章一般性評論/建議

  • Visiongain 概述
  • 給參賽者的建議
Product Code: PHA1314

The global Translational Regenerative Medicine market is estimated to grow at a CAGR of 24.3% by 2034

The Translational Regenerative Medicine Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Rising Chronic Diseases Driving Industry Growth

The global landscape of healthcare is witnessing a paradigm shift driven by the escalating prevalence of chronic diseases. Conditions such as cardiovascular diseases, diabetes, neurodegenerative disorders, and autoimmune diseases pose a significant burden on healthcare systems worldwide. In response to this growing health crisis, the field of Translational regenerative medicine (TRM) has emerged as a beacon of hope, offering innovative solutions to address the root causes of these chronic ailments. Translational regenerative medicine focuses on harnessing the body's innate regenerative capabilities to repair, replace, or regenerate damaged tissues and organs. Stem cell therapies, tissue engineering, and other regenerative approaches hold the potential to revolutionize the treatment landscape for chronic diseases by addressing the underlying causes rather than merely managing symptoms. Translational regenerative medicine allows for the development of personalized therapies tailored to individual patient needs. This approach is particularly relevant in the context of chronic diseases where heterogeneity in patient responses is common. Advances in stem cell research, including the use of induced pluripotent stem cells (iPSCs) and adult stem cells, offer a diverse range of regenerative possibilities. Stem cell-based therapies hold promise for conditions such as diabetes, where the replacement of damaged pancreatic cells could restore normal insulin production.

High Development Costs Associated with Translational Regenerative Medicine

The initial phases of developing translational regenerative medicine therapies involve extensive research to understand the underlying biology and mechanisms. This early-stage research requires funding for laboratory equipment, personnel, and consumables. Clinical trials represent a major portion of the development costs. These trials are essential for evaluating the safety and efficacy of regenerative therapies in human subjects. Costs include patient recruitment, monitoring, regulatory compliance, and data analysis, all of which demand substantial financial resources. Transitioning from laboratory-scale production to large-scale manufacturing presents unique challenges. Ensuring the reproducibility, quality, and safety of regenerative therapies on a larger scale requires investment in manufacturing infrastructure and process optimization. Successfully bringing a regenerative medicine product to market is just the beginning. Companies face additional costs related to market access, including marketing, distribution, and post-marketing surveillance. These activities are crucial for ensuring widespread adoption and continued success.

What Questions Should You Ask before Buying a Market Research Report?

How is the Translational Regenerative Medicine Market evolving?

What is driving and restraining the Translational Regenerative Medicine Market?

How will each Translational Regenerative Medicine submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each Translational Regenerative Medicine submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading Translational Regenerative Medicine Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the Translational Regenerative Medicine projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of Translational

Regenerative Medicine projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the Translational Regenerative Medicine Market?

Where is the Translational Regenerative Medicine Market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Translational Regenerative Medicine Market today, and over the next 10 years:

Our 270-page report provides 104 tables and 144 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Translational Regenerative Medicine Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report

By Product

Stem Cell Therapy: Autologous, Allogenic

Tissue Engineering: Scaffold, Hydrogels

Gene Therapy

Others

By Application

Oncology

Dermatology

Musculoskeletal

Neurology

Cardiovascular

Wound Healing

Ophthalmology

Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 17 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Spain

Italy

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

MEA

GCC

South Africa

Rest of MEA

The report also includes profiles and for some of the leading companies in the Translational Regenerative Medicine Market 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

Amgen Inc.

Anterogen Co., Ltd.

AVITA Medical, Inc.

Biosolutions Ltd.

bluebird bio, Inc.

Bristol-Myers Squibb Company

Gilead Sciences, Inc.

Integra LifeSciences

Mesoblast Ltd.

Novartis AG

Organogenesis Inc.

Sarepta Therapeutics, Inc.

Smith+Nephew

TERUMO BCT, INC.

Overall world revenue for Translational Regenerative Medicine Market, 2024 to 2034 in terms of value the market will surpass US$77.0 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Translational Regenerative Medicine Market 2024 to 2034 report help you?

In summary, our 270-page report provides you with the following knowledge:

Revenue forecasts to 2034 for Translational Regenerative Medicine Market 2024 to 2034, with forecasts for product and application each forecasted at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 20 key national markets - See forecasts for the Translational Regenerative Medicine Market, 2024 to 2034 in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 14 of the major companies involved in the Translational Regenerative Medicine Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Translational Regenerative Medicine Market 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Translational Regenerative Medicine Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Increasing Strategic Activities and Collaborations
      • 3.2.1.2 Rise in Research and Development Projects
      • 3.2.1.3 Surging Government Support
      • 3.2.1.4 Growing Focus on Personalized Medicine
      • 3.2.1.5 Emerging Applications in New Therapeutic Areas
      • 3.2.1.6 Increasing Collaborations and Partnerships by Major Market Players
      • 3.2.1.7 Increasing Regulatory Approvals in Regenerative Medicine
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Substantial Number of Product Recalls
      • 3.2.2.2 Unapproved Products in the Market
      • 3.2.2.3 Reimbursement Policies
      • 3.2.2.4 High Cost of Treatments
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Growing Research Partnership in Developed and Developing Countries Across the Globe
      • 3.2.3.2 Growing Awareness About the Advances in Medical Research
      • 3.2.3.3 Growing Investment and Funding
      • 3.2.3.4 Harnessing the Potential of 3D Printing
      • 3.2.3.5 Integration with Artificial Intelligence and Big Data
      • 3.2.3.6 Growing Number of Organ Transplants
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Porter's Five Forces Analysis
    • 3.4.1 Bargaining Power of Suppliers
    • 3.4.2 Bargaining Power of Buyers
    • 3.4.3 Competitive Rivalry
    • 3.4.4 Threat from Substitutes
    • 3.4.5 Threat of New Entrants
  • 3.5 PEST Analysis

4 Translational Regenerative Medicine Market Analysis by Product

  • 4.1 Key Findings
  • 4.2 Application Segment: Market Attractiveness Index
  • 4.3 Translational Regenerative Medicine Market Size Estimation and Forecast by Product
  • 4.4 Stem Cell Therapy
    • 4.4.1 Translational Regenerative Medicine Market Size Estimation and Forecast by Stem Cell Therapy
    • 4.4.2 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.4.3 Market Share by Region, 2024 & 2034 (%)
    • 4.4.4 Autologous Stem Cell Therapy
      • 4.4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
      • 4.4.4.2 Market Share by Region, 2024 & 2034 (%)
    • 4.4.5 Allogenic
      • 4.4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
      • 4.4.5.2 Market Share by Region, 2024 & 2034 (%)
  • 4.5 Tissue Engineering
    • 4.5.1 Translational Regenerative Medicine Market Size Estimation and Forecast by Tissue Engineering
    • 4.5.2 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.5.3 Market Share by Region, 2024 & 2034 (%)
    • 4.5.4 Scaffold
      • 4.5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
      • 4.5.4.2 Market Share by Region, 2024 & 2034 (%)
    • 4.5.5 Hydrogels
      • 4.5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
      • 4.5.5.2 Market Share by Region, 2024 & 2034 (%)
  • 4.6 Gene Therapy
    • 4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.6.2 Market Share by Region, 2024 & 2034 (%)
  • 4.7 Others
    • 4.7.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.7.2 Market Share by Region, 2024 & 2034 (%)

5 Translational Regenerative Medicine Market Analysis by Application

  • 5.1 Key Findings
  • 5.2 Application Segment: Market Attractiveness Index
  • 5.3 Translational Regenerative Medicine Market Size Estimation and Forecast by Application
  • 5.4 Oncology
    • 5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.4.2 Market Share by Region, 2024 & 2034 (%)
  • 5.5 Dermatology
    • 5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.5.2 Market Share by Region, 2024 & 2034 (%)
  • 5.6 Musculoskeletal
    • 5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.6.2 Market Share by Region, 2024 & 2034 (%)
  • 5.7 Neurology
    • 5.7.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.7.2 Market Share by Region, 2024 & 2034 (%)
  • 5.8 Cardiovascular
    • 5.8.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.8.2 Market Share by Region, 2024 & 2034 (%)
  • 5.9 Wound Healing
    • 5.9.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.9.2 Market Share by Region, 2024 & 2034 (%)
  • 5.10 Ophthalmology
    • 5.10.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.10.2 Market Share by Region, 2024 & 2034 (%)
  • 5.11 Others
    • 5.11.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.11.2 Market Share by Region, 2024 & 2034 (%)

6 Translational Regenerative Medicine Market Analysis by Region

  • 6.1 Key Findings
  • 6.2 Regional Market Size Estimation and Forecast

7 North America Translational Regenerative Medicine Market Analysis

  • 7.1 Key Findings
  • 7.2 North America Translational Regenerative Medicine Market Attractiveness Index
  • 7.3 North America Translational Regenerative Medicine Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 7.4 North America Translational Regenerative Medicine Market Size Estimation and Forecast by Country
  • 7.5 North America Translational Regenerative Medicine Market Size Estimation and Forecast by Product
  • 7.6 North America Translational Regenerative Medicine Market Size Estimation and Forecast by Application
  • 7.7 U.S. Translational Regenerative Medicine Market Analysis
  • 7.8 Canada Translational Regenerative Medicine Market Analysis

8 Europe Translational Regenerative Medicine Market Analysis

  • 8.1 Key Findings
  • 8.2 Europe Translational Regenerative Medicine Market Attractiveness Index
  • 8.3 Europe Translational Regenerative Medicine Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 8.4 Europe Translational Regenerative Medicine Market Size Estimation and Forecast by Country
  • 8.5 Europe Translational Regenerative Medicine Market Size Estimation and Forecast by Product
  • 8.6 Europe Translational Regenerative Medicine Market Size Estimation and Forecast by Application
  • 8.7 Germany Translational Regenerative Medicine Market Analysis
  • 8.8 France Translational Regenerative Medicine Market Analysis
  • 8.9 UK Translational Regenerative Medicine Market Analysis
  • 8.10 Italy Translational Regenerative Medicine Market Analysis
  • 8.11 Spain Translational Regenerative Medicine Market Analysis
  • 8.12 Russia Translational Regenerative Medicine Market Analysis
  • 8.13 Rest of Europe Translational Regenerative Medicine Market Analysis

9 Asia Pacific Translational Regenerative Medicine Market Analysis

  • 9.1 Key Findings
  • 9.2 Asia Pacific Translational Regenerative Medicine Market Attractiveness Index
  • 9.3 Asia Pacific Translational Regenerative Medicine Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 9.4 Asia Pacific Translational Regenerative Medicine Market Size Estimation and Forecast by Country
  • 9.5 Asia Pacific Translational Regenerative Medicine Market Size Estimation and Forecast by Product
  • 9.6 Asia Pacific Translational Regenerative Medicine Market Size Estimation and Forecast by Application
  • 9.7 Japan Translational Regenerative Medicine Market Analysis
  • 9.8 China Translational Regenerative Medicine Market Analysis
  • 9.9 India Translational Regenerative Medicine Market Analysis
  • 9.10 Australia Translational Regenerative Medicine Market Analysis
  • 9.11 South Korea Translational Regenerative Medicine Market Analysis
  • 9.12 Rest of Asia Pacific Translational Regenerative Medicine Market Analysis

10 Latin America Translational Regenerative Medicine Market Analysis

  • 10.1 Key Findings
  • 10.2 Latin America Translational Regenerative Medicine Market Attractiveness Index
  • 10.3 Latin America Translational Regenerative Medicine Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 10.4 Latin America Translational Regenerative Medicine Market Size Estimation and Forecast by Country
  • 10.5 Latin America Translational Regenerative Medicine Market Size Estimation and Forecast by Product
  • 10.6 Latin America Translational Regenerative Medicine Market Size Estimation and Forecast by Application
  • 10.7 Brazil Translational Regenerative Medicine Market Analysis
  • 10.8 Mexico Translational Regenerative Medicine Market Analysis
  • 10.9 Rest of Latin America Translational Regenerative Medicine Market Analysis

11 MEA Translational Regenerative Medicine Market Analysis

  • 11.1 Key Findings
  • 11.2 MEA Translational Regenerative Medicine Market Attractiveness Index
  • 11.3 MEA Translational Regenerative Medicine Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 11.4 MEA Translational Regenerative Medicine Market Size Estimation and Forecast by Country
  • 11.5 MEA Translational Regenerative Medicine Market Size Estimation and Forecast by Product
  • 11.6 MEA Translational Regenerative Medicine Market Size Estimation and Forecast by Application
  • 11.7 GCC Translational Regenerative Medicine Market Analysis
  • 11.8 South Africa Translational Regenerative Medicine Market Analysis
  • 11.9 Rest of MEA Translational Regenerative Medicine Market Analysis

12 Company Profiles

  • 12.1 Competitive Landscape, 2022
  • 12.2 Strategic Outlook
  • 12.3 Amgen Inc.
    • 12.3.1 Company Snapshot
    • 12.3.2 Company Overview
    • 12.3.3 Financial Analysis
      • 12.3.3.1 Net Revenue, 2017-2022
      • 12.3.3.2 R&D, 2017-2022
      • 12.3.3.3 Regional Market Shares, 2022
    • 12.3.4 Product Benchmarking
    • 12.3.5 Strategic Outlook
  • 12.4 Anterogen Co., Ltd.
    • 12.4.1 Company Snapshot
    • 12.4.2 Company Overview
    • 12.4.3 Product Benchmarking
  • 12.5 AVITA Medical, Inc.
    • 12.5.1 Company Snapshot
    • 12.5.2 Company Overview
    • 12.5.3 Financial Analysis
      • 12.5.3.1 Net Revenue, 2017-2022
      • 12.5.3.2 R&D, 2017-2022
    • 12.5.4 Product Benchmarking
    • 12.5.5 Strategic Outlook
  • 12.6 Biosolutions Ltd.
    • 12.6.1 Company Snapshot
    • 12.6.2 Company Overview
    • 12.6.3 Product Benchmarking
    • 12.6.4 Strategic Outlook
  • 12.7 bluebird bio, Inc.
    • 12.7.1 Company Snapshot
    • 12.7.2 Company Overview
    • 12.7.3 Financial Analysis
      • 12.7.3.1 Net Revenue, 2017-2022
      • 12.7.3.2 R&D, 2017-2022
    • 12.7.4 Product Benchmarking
    • 12.7.5 Strategic Outlook
  • 12.8 Bristol-Myers Squibb Company
    • 12.8.1 Company Snapshot
    • 12.8.2 Company Overviews
    • 12.8.3 Financial Analysis
      • 12.8.3.1 Net Revenue, 2017-2022
      • 12.8.3.2 R&D, 2017-2022
      • 12.8.3.3 Regional Market Shares, 2022
    • 12.8.4 Product Benchmarking
    • 12.8.5 Strategic Outlook
  • 12.9 Gilead Sciences, Inc.
    • 12.9.1 Company Snapshot
    • 12.9.2 Company Overview
    • 12.9.3 Financial Analysis
      • 12.9.3.1 Net Revenue, 2017-2022
      • 12.9.3.2 R&D, 2017-2022
      • 12.9.3.3 Regional Market Shares, 2022
    • 12.9.4 Product Benchmarking
    • 12.9.5 Strategic Outlook
  • 12.10 Integra LifeSciences
    • 12.10.1 Company Snapshot
    • 12.10.2 Company Overview
    • 12.10.3 Financial Analysis
      • 12.10.3.1 Net Revenue, 2017-2022
      • 12.10.3.2 R&D, 2017-2022
      • 12.10.3.3 Regional Market Shares, 2022
    • 12.10.4 Product Benchmarking
    • 12.10.5 Strategic Outlook
  • 12.11 Mesoblast Ltd.
    • 12.11.1 Company Snapshot
    • 12.11.2 Company Overview
    • 12.11.3 Financial Analysis
      • 12.11.3.1 Net Revenue, 2017-2022
      • 12.11.3.2 R&D, 2017-2022
    • 12.11.4 Product Benchmarking
    • 12.11.5 Strategic Outlook
  • 12.12 Novartis AG
    • 12.12.1 Company Snapshot
    • 12.12.2 Company Overview
    • 12.12.3 Financial Analysis
      • 12.12.3.1 Net Revenue, 2017-2022
      • 12.12.3.2 R&D, 2017-2022
      • 12.12.3.3 Regional Market Shares, 2022
    • 12.12.4 Product Benchmarking
    • 12.12.5 Strategic Outlook
  • 12.13 Organogenesis Inc.
    • 12.13.1 Company Snapshot
    • 12.13.2 Company Overview
    • 12.13.3 Financial Analysis
      • 12.13.3.1 Net Revenue, 2017-2022
      • 12.13.3.2 R&D, 2017-2022
    • 12.13.4 Product Benchmarking
    • 12.13.5 Strategic Outlook
  • 12.14 Sarepta Therapeutics, Inc.
    • 12.14.1 Company Snapshot
    • 12.14.2 Company Overview
    • 12.14.3 Financial Analysis
      • 12.14.3.1 Net Revenue, 2017-2022
      • 12.14.3.2 R&D, 2017-2022
    • 12.14.4 Product Benchmarking
    • 12.14.5 Strategic Outlook
  • 12.15 Smith+Nephew
    • 12.15.1 Company Snapshot
    • 12.15.2 Company Overview
    • 12.15.3 Financial Analysis
      • 12.15.3.1 Net Revenue, 2017-2022
      • 12.15.3.2 R&D, 2017-2022
      • 12.15.3.3 Regional Market Shares, 2022
    • 12.15.4 Product Benchmarking
    • 12.15.5 Strategic Outlook
  • 12.16 TERUMO BCT, INC.
    • 12.16.1 Company Snapshot
    • 12.16.2 Company Overview
    • 12.16.3 Financial Analysis
      • 12.16.3.1 Net Revenue, 2017-2022
      • 12.16.3.2 Regional Market Shares, 2021
    • 12.16.4 Product Benchmarking
    • 12.16.5 Strategic Outlook

13 Conclusion and Recommendations

  • 13.1 Concluding Remarks from Visiongain
  • 13.2 Recommendations for Market Players

List of Tables

  • Table 1 Translational Regenerative Medicine Market Snapshot, 2024 & 2034 (US$ Billion, CAGR %)
  • Table 2 Translational Regenerative Medicine Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 3 Translational Regenerative Medicine Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 4 Translational Regenerative Medicine Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 5 Translational Regenerative Medicine Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 6 Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 7 Translational Regenerative Medicine Market Forecast by Stem Cell Therapy, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 8 Stem Cell Therapy Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 9 Autologous Stem Cell Therapy Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 10 Allogenic Stem Cell Therapy Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 11 Tissue Engineering Market Forecast by Stem Cell Therapy, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 12 Tissue Engineering Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 13 Scaffold Tissue Engineering Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 14 Hydrogels Tissue Engineering Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 15 Gene Therapy Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 16 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 17 Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 18 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 19 Dermatology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 20 Musculoskeletal Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 21 Neurology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 22 Cardiovascular Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 23 Wound Healing Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 24 Ophthalmology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 25 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 26 Translational Regenerative Medicine Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 27 North America Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 28 Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 29 Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 30 U.S. Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 31 Canada Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 32 Europe Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 33 Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 34 Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 35 Germany Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 36 France Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 37 UK Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 38 Italy Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 39 Spain Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 40 Russia Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 41 Rest of Europe Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 42 Asia Pacific Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 43 Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 44 Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 45 Japan Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 46 China Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 47 India Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 48 Australia Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 49 South Korea Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 50 Rest of Asia Pacific Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 51 Latin America Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 52 Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 53 Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 54 Brazil Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 55 Mexico Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 56 Rest of Latin America Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 57 MEA Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 58 Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 59 Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 60 GCC Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 61 South Africa Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 62 Rest of MEA Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 63 Strategic Outlook
  • Table 64 Amgen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 65 Amgen Inc.: Product Benchmarking
  • Table 66 Amgen Inc. : Strategic Outlook
  • Table 67 Anterogen Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 68 Anterogen Co., Ltd.: Product Benchmarking
  • Table 69 AVITA Medical, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 70 AVITA Medical, Inc.: Product Benchmarking
  • Table 71 AVITA Medical, Inc.: Strategic Outlook
  • Table 72 Biosolutions Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 73 Biosolutions Ltd.: Product Benchmarking
  • Table 74 Biosolutions Ltd.: Strategic Outlook
  • Table 75 bluebird bio, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 76 bluebird bio, Inc.: Product Benchmarking
  • Table 77 bluebird bio, Inc.: Strategic Outlook
  • Table 78 Bristol-Myers Squibb Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 79 Bristol-Myers Squibb Company: Product Benchmarking
  • Table 80 Bristol-Myers Squibb Company: Strategic Outlook
  • Table 81 Gilead Sciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 82 Gilead Sciences, Inc.: Product Benchmarking
  • Table 83 Gilead Sciences, Inc.: Strategic Outlook
  • Table 84 Integra LifeSciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 85 Integra LifeSciences: Product Benchmarking
  • Table 86 Integra LifeSciences: Strategic Outlook
  • Table 87 Mesoblast Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 88 Mesoblast Ltd.: Product Benchmarking
  • Table 89 Mesoblast Ltd.: Strategic Outlook
  • Table 90 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 91 Novartis AG: Product Benchmarking
  • Table 92 Novartis AG: Strategic Outlook
  • Table 93 Organogenesis Inc.:(CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 94 Organogenesis Inc.: Product Benchmarking
  • Table 95 Organogenesis Inc.: Strategic Outlook
  • Table 96 Sarepta Therapeutics, Inc. :(CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 97 Sarepta Therapeutics, Inc.: Product Benchmarking
  • Table 98 Sarepta Therapeutics, Inc..: Strategic Outlook
  • Table 99 Smith+Nephew: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 100 Smith+Nephew: Product Benchmarking
  • Table 101 Smith+Nephew: Strategic Outlook
  • Table 102 TERUMO BCT, INC.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 103 TERUMO BCT, INC.: Product Benchmarking
  • Table 104 TERUMO BCT, INC.: Strategic Outlook
  •  

List of Figures

  • Figure 1 Translational Regenerative Medicine Market Segmentation
  • Figure 2 Translational Regenerative Medicine Market by Product: Market Attractiveness Index
  • Figure 3 Translational Regenerative Medicine Market by Application: Market Attractiveness Index
  • Figure 4 Translational Regenerative Medicine Market Attractiveness Index by Region
  • Figure 5 Translational Regenerative Medicine Market: Market Dynamics
  • Figure 6 Translational Regenerative Medicine Market by Region, 2024-2034 (US$ Billion, AGR %): "V" Shaped Recovery
  • Figure 7 Translational Regenerative Medicine Market by Region, 2024-2034 (US$ Billion, AGR %): "U" Shaped Recovery
  • Figure 8 Translational Regenerative Medicine Market by Region, 2024-2034 (US$ Billion, AGR %): "W" Shaped Recovery
  • Figure 9 Translational Regenerative Medicine Market by Region, 2024-2034 (US$ Billion, AGR %): "L" Shaped Recovery
  • Figure 10 Translational Regenerative Medicine Market: Porter's Five Forces Analysis
  • Figure 11 Translational Regenerative Medicine Market: PEST Analysis
  • Figure 12 Translational Regenerative Medicine Market by Product: Market Attractiveness Index
  • Figure 13 Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
  • Figure 14 Translational Regenerative Medicine Market Share Forecast by Product, 2024 2029, 2034 (%)
  • Figure 15 Stem Cell Therapy Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 16 Stem Cell Therapy Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 17 Autologous Stem Cell Therapy Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 18 Autologous Stem Cell Therapy Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 19 Allogenic Stem Cell Therapy Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 20 Allogenic Stem Cell Therapy Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 21 Tissue Engineering Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 22 Tissue Engineering Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 23 Scaffold Tissue Engineering Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 24 Scaffold Tissue Engineering Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 25 Hydrogels Tissue Engineering Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 26 Hydrogels Tissue Engineering Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 27 Gene Therapy Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 28 Gene Therapy Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 29 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 30 Others Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 31 Translational Regenerative Medicine Market by Application: Market Attractiveness Index
  • Figure 32 Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
  • Figure 33 Translational Regenerative Medicine Market Share Forecast by Application, 2024 2029, 2034 (%)
  • Figure 34 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 35 Oncology Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 36 Dermatology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 37 Dermatology Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 38 Musculoskeletal Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 39 Musculoskeletal Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 40 Neurology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 41 Neurology Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 42 Cardiovascular Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 43 Cardiovascular Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 44 Wound Healing Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 45 Wound Healing Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 46 Ophthalmology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 47 Ophthalmology Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 48 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 49 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 50 Translational Regenerative Medicine Market Forecast by Region 2023 and 2033 (Revenue, CAGR %)
  • Figure 51 Translational Regenerative Medicine Market Share Forecast by Region 2024 2029, 2034 (%)
  • Figure 52 Translational Regenerative Medicine Market by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 53 North America Translational Regenerative Medicine Market Attractiveness Index
  • Figure 54 North America Translational Regenerative Medicine Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 55 North America Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 56 North America Translational Regenerative Medicine Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 57 North America Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
  • Figure 58 North America Translational Regenerative Medicine Market Share Forecast by Product, 2024 & 2034 (%)
  • Figure 59 North America Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
  • Figure 60 North America Translational Regenerative Medicine Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 61 U.S. Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 62 Canada Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 63 Europe Translational Regenerative Medicine Market Attractiveness Index
  • Figure 64 Europe Translational Regenerative Medicine Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 65 Europe Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 66 Europe Translational Regenerative Medicine Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 67 Europe Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
  • Figure 68 Europe Translational Regenerative Medicine Market Share Forecast by Product, 2024 & 2034 (%)
  • Figure 69 Europe Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
  • Figure 70 Europe Translational Regenerative Medicine Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 71 Germany Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 72 France Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 73 UK Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 74 Italy Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 75 Spain Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 76 Russia Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 77 Rest of Europe Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 78 Asia Pacific Translational Regenerative Medicine Market Attractiveness Index
  • Figure 79 Asia Pacific Translational Regenerative Medicine Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 80 Asia Pacific Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 81 Asia Pacific Translational Regenerative Medicine Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 82 Asia Pacific Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
  • Figure 83 Asia Pacific Translational Regenerative Medicine Market Share Forecast by Product, 2024 & 2034 (%)
  • Figure 84 Asia Pacific Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
  • Figure 85 Asia Pacific Translational Regenerative Medicine Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 86 Japan Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 87 China Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 88 India Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 89 Australia Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 90 South Korea Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 91 Rest of Asia Pacific Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 92 Latin America Translational Regenerative Medicine Market Attractiveness Index
  • Figure 93 Latin America Translational Regenerative Medicine Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 94 Latin America Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 95 Latin America Translational Regenerative Medicine Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 96 Latin America Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
  • Figure 97 Latin America Translational Regenerative Medicine Market Share Forecast by Product, 2024 & 2034 (%)
  • Figure 98 Latin America Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
  • Figure 99 Latin America Translational Regenerative Medicine Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 100 Brazil Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 101 Mexico Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 102 Rest of Latin America Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 103 MEA Translational Regenerative Medicine Market Attractiveness Index
  • Figure 104 MEA Translational Regenerative Medicine Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 105 MEA Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 106 MEA Translational Regenerative Medicine Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 107 MEA Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
  • Figure 108 MEA Translational Regenerative Medicine Market Share Forecast by Product, 2024 & 2034 (%)
  • Figure 109 MEA Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
  • Figure 110 MEA Translational Regenerative Medicine Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 111 GCC Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 112 South Africa Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 113 Rest of MEA Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 114 Translational Regenerative Medicine Market: Company Share, 2022
  • Figure 115 Amgen Inc.: Net Revenue, 2017-2022 (US$ Million, AGR %)
  • Figure 116 Amgen Inc.: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 117 Amgen Inc.: Regional Market Shares, 2022
  • Figure 118 AVITA Medical, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 119 AVITA Medical, Inc.: R&D, 2017-2022 (US$ Million, AGR %)
  • Figure 120 bluebird bio, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 121 bluebird bio, Inc.: R&D, 2017-2022 (US$ Million, AGR %)
  • Figure 122 Bristol-Myers Squibb Company: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 123 Bristol-Myers Squibb Company: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 124 Bristol-Myers Squibb Company: Regional Market Shares, 2022
  • Figure 125 Gilead Sciences, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 126 Gilead Sciences, Inc.: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 127 Gilead Sciences, Inc.: Regional Market Shares, 2022
  • Figure 128 Integra LifeSciences: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 129 Integra LifeSciences: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 130 Integra LifeSciences: Regional Market Shares, 2022
  • Figure 131 Mesoblast Ltd.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 132 Mesoblast Ltd.: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 133 Novartis AG: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 134 Novartis AG: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 135 Novartis AG: Regional Market Shares, 2022
  • Figure 136 Organogenesis Inc.: Net Revenue, 2017-2022 (US$ million, AGR%)
  • Figure 137 Organogenesis Inc.: R&D, 2017-2022 (US$ million, AGR%)
  • Figure 138 Sarepta Therapeutics, Inc..: Net Revenue, 2017-2022 (US$ million, AGR%)
  • Figure 139 Sarepta Therapeutics, Inc.: R&D, 2017-2022 (US$ million, AGR%)
  • Figure 140 Smith+Nephew: Net Revenue, 2017-2022 (US$ million, AGR%)
  • Figure 141 Smith+Nephew: R&D, 2017-2022 (US$ million, AGR%)
  • Figure 142 Smith+Nephew: Regional Market Shares, 2022
  • Figure 143 TERUMO BCT, INC.: Net Revenue, 2017-2022 (US$ million, AGR%)
  • Figure 144 TERUMO BCT, INC.: Regional Market Shares, 2022